Inovio faces October 30 FDA decision for Inovio Pharmaceuticals stock

Published on 10/24/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA action on INO-3107 is set for October 30, 2026. Inovio Pharmaceuticals stock last traded at USD 0.90 on the Nasdaq on October 23, 2026.

Regulatory and financial picture

The FDA action date for INO-3107 is October 30, 2026.
Inovio reported a USD 6.00 million net loss for the second quarter of 2026.
Inovio Pharmaceuticals stock last traded at USD 0.90 on Nasdaq on October 23, 2026.
Cash and short-term investments totaled USD 36.70 million on June 30, 2026.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals (US45773H4092) faces an FDA action date of October 30, 2026, for its INO-3107 application. The company discussed the regulatory timetable and its second-quarter finances in an earnings call carried by Yahoo Finance. Inovio Pharmaceuticals stock last traded at USD 0.90 on Nasdaq on October 23, 2026 at 4:00 p.m. ET.

FDA date keeps the focus on INO-3107

The October 30 date is the next major corporate milestone for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis. Yahoo Finance reported that the FDA review had completed its late-cycle review meeting and scheduled pre-licensure inspections by the August 12, 2026 call. Management also said the company expected its cash runway to extend into late first quarter 2027 and through a potential launch if the treatment is approved.

Second-quarter loss narrowed

Inovio reported a net loss of USD 6.00 million, or USD 0.07 per share, for the second quarter of 2026, compared with a USD 23.50 million loss, or USD 0.61 per share, in the second quarter of 2025, according to Yahoo Finance. Operating expenses fell from USD 23.10 million to USD 18.60 million over the same comparison, a 19.00 percent decrease. The reported improvement included a USD 13.90 million non-cash gain linked to warrant liabilities.

Cash and valuation frame the risk

Cash and short-term investments stood at USD 36.70 million on June 30, 2026, versus USD 58.50 million on December 31, 2025. In July, Inovio raised approximately USD 18.30 million in net proceeds, while management projected an operational net cash burn of approximately USD 18.00 million for the third quarter of 2026.

Inovio Pharmaceuticals had a market capitalization of USD 62.00 million on October 23, 2026. Its Nasdaq 52-week range was USD 0.56 to USD 2.72, placing the last price below the yearly high and above the yearly low. The company operates in the Healthcare sector and Biotechnology industry.

What comes next for investors?

The October 30, 2026 FDA action date is the next dated event. The Q2 loss comparison shows lower reported costs and a smaller loss, but the cash figures keep financing and launch preparation central to the investment case.

Home-market price remains the daily anchor

On Nasdaq, Inovio Pharmaceuticals stock last traded at USD 0.90 on October 23, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 0.56 to USD 2.72 as of the same date.